- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
What We're Reading: Drug Makers Take Cautious Approach on Off-Label Promotion
What we're reading, January 2, 2017: drug makers are taking a cautious approach to off-label promotion; Republicans eye changes to Medicaid under Trump administration; and the impact of geography on health.
Almost a year ago, a court ruling may have opened the gate for drug makers to promote off-label uses for medications, but most companies are playing it safe, for now. According to MedPage Today, companies are taking a “wait-and-see” approach and avoiding and promotion of off-label uses that would put them into dispute with the FDA. Traditionally, the FDA has a zero-tolerance policy for off-label promotion, but the court ruling means the agency can’t outright ban the this type of communication.
Republicans are planning a lot of changes for healthcare under the Trump administration. In addition to repealing and replacing the Affordable Care Act and weighing a possible privatization of veterans’ medical care, the GOP is eyeing an overhaul to Medicaid, reported AP. Trump and Republicans are considering using block grants for the program, which supporters say will rein in spending. Critics are worried about big cuts. Currently, there are 70 million people covered by Medicaid.
Where a person lives can have a big impact on his or her health. A recent report highlighted how much of an impact geography can have with the finding that people in Mississippi live to 75, on average, while people in Hawaii can live longer than 81 years. The Washington Post outlined numerous interventions occurring across the country that are based on geographic data, such as a home inspection program in one Connecticut city based on data that there was a high rate of asthma-related hospitalizations.
California Aims for Equity by Redefining Cancer Care
December 8th 2023Authors highlight key aspects of the California Cancer Care Equity Act, including its focus on Medi-Cal beneficiaries, the requirement for managed care plans to contract with specialized cancer centers, and the definition of complex cancers.
Read More
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
Patients With RA in Remission Withdrawing From TNF Inhibition Show Flare Increases
December 8th 2023New data presented at ACR 2023 highlighted the differences in rates of flares and Boolean 2.0 remission rates compared to patients with rheumatoid arthritis who continued a tumor necrosis factor inhibitor (TNFi).
Read More
Insufficient Data, Disparities Plague Lung Cancer Risk Factor Documentation
September 24th 2023On this episode of Managed Care Cast, we speak with the senior author of a study published in the September 2023 issue of The American Journal of Managed Care® on the importance of adequate and effective lung cancer risk factor documentation to determine a patient's eligibility for screening.
Listen
Research Reveals the Role of Structural Racism in Lung Cancer Risk
December 7th 2023Spanning 22 studies, the analysis illuminated housing disparities, occupational hazards, unequal health care access, economic inequality, and discriminatory industry practices and how they collectively contribute to heightened lung cancer risks.
Read More
Refining Precision Prevention for Benign Breast Disease
December 7th 2023Many questions remain surrounding accurately classifying the risk of developing invasive breast cancer associated with the benign breast disease diagnoses of nonproliferative lesions and proliferative changes without atypia.
Read More
